GlassScriptPhysician profile
Michael Chin Yang
NPI 1255448569
$1,422.88
in general payments reported to CMS, 2019-2025
20 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $71.42 · 2021: $363 · 2022: $166 · 2023: $247 · 2024: $173 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $631.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $223.63 | 2023-2025 | Veozah |
| Abbvie INC. | $160.94 | 2020-2025 | Lo Loestrin Fe, Orilissa |
| Organon LLC | $136.75 | 2022-2025 | Nexplanon |
| Integra Lifesciences Corporation | $123.97 | 2021 | |
| Lupin INC. | $122.10 | 2019 | |
| Myovant Sciences INC. | $93.19 | 2021-2022 | |
| Agile Therapeutics, INC. | $80.50 | 2021-2023 | Twirla |
| Hologic Sales and Service, LLC | $68.06 | 2019-2020 | |
| Exeltis, USA INC. | $57.50 | 2021-2025 | Slynd |
| Merck Sharp & Dohme LLC | $54.03 | 2020-2024 | Gardasil, Gardasil 9 |
| Minerva Surgical, INC | $44.24 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $41.04 | 2022-2023 | Exparel |
| Smith+Nephew, INC. | $35.89 | 2023-2024 | Stravix |
| Pfizer INC. | $31.62 | 2023-2024 | |
| Mission Pharmacal Company | $28.85 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.77 | 2025 | |
| Innovation Technologies INC | $24.20 | 2025 | Irrisept |
| Allergan, INC. | $23.96 | 2019 | |
| Evofem Biosciences, INC. | $23.60 | 2021 | |
| Avion Pharmaceuticals | $20.04 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.